SLC2A1 and epilepsy: Subjects with an epileptic phenotype caused by SLC2A1 mutation and coding for Glucose Transporter Type 1 (GLUT-1) that prevents a correct glucose share to the CNS, represent a tangible example of the great potentiality of pharmacogenomics in epilepsy treatment.